Free Trial

ImmunoPrecise Antibodies Q3 2025 Earnings Report

ImmunoPrecise Antibodies logo
$0.36 -0.02 (-4.25%)
As of 04:00 PM Eastern

ImmunoPrecise Antibodies EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.06
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

ImmunoPrecise Antibodies Revenue Results

Actual Revenue
$4.23 million
Expected Revenue
$6.59 million
Beat/Miss
Missed by -$2.35 million
YoY Revenue Growth
N/A

ImmunoPrecise Antibodies Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Remove Ads

ImmunoPrecise Antibodies Earnings Headlines

Partner with Elon Musk on Project Colossus… Before May 1st
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
ImmunoPrecise Antibodies reports Q3 EPS (C$0.66) vs. (C$0.10) last year
See More ImmunoPrecise Antibodies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunoPrecise Antibodies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunoPrecise Antibodies and other key companies, straight to your email.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies (NASDAQ:IPA), together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

View ImmunoPrecise Antibodies Profile

More Earnings Resources from MarketBeat